NCT05910112 (PROSPECT) is a clinical trial of Pleural interventions in Pleural Diseases, sponsored by University of Oxford.

Who is sponsoring NCT05910112?

NCT05910112 is sponsored by University of Oxford.

What drugs are being tested in NCT05910112?

Interventions in NCT05910112: Pleural interventions.

What condition does NCT05910112 study?

NCT05910112 studies Pleural Diseases, Pleural Mesothelioma, Pneumothorax, Pleural Effusion, Pleural Infection, Pleural Neoplasms, Pleural Metastases, Pleural Effusion, Malignant, Procedural Complication, Complications, Pulmonary.

Is NCT05910112 still recruiting?

NCT05910112 is currently status unknown. Last updated 18 June 2023.

Last reviewed 2023-06-18 · How we verify

NCT05910112: PROSPECT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Data Collection on Clinical, Radiological and Patient Reported Outcomes After Pleural Intervention

Status unknown Last updated 18 June 2023

What this trial tests

trial testing Pleural interventions in Pleural Diseases in 2,000 participants. Status unknown.

Timeline

1 September 2020

Primary endpoint
1 August 2024

1 August 2024

Quick facts

Lead sponsor	University of Oxford
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	2,000
Start date	1 September 2020
Primary completion	1 August 2024
Estimated completion	1 August 2024
Sites	1 location across United Kingdom

Drugs / interventions tested

Pleural interventions

Conditions studied

Pleural Diseases — all drugs for Pleural Diseases →
Pleural Mesothelioma — all drugs for Pleural Mesothelioma →
Pneumothorax — all drugs for Pneumothorax →
Pleural Effusion — all drugs for Pleural Effusion →

Sponsor

University of Oxford

Who can join

18 and older, any sex, with Pleural Diseases or Pleural Mesothelioma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The PROSPECT study aims to look at the number of problems or side effects which occur after patients have had a procedure completed to remove fluid or air from the space between the lung and the chest wall. Other information will also be collected to see whether anything else affects which patients have problems after the procedure such as bleeding or infection. This study will also investigate whether it is possible to find out which patients are likely to feel a lot better after the procedure. Not all patients feel significantly better but it is not clear why this is. There are a number of different reasons patients may not feel better, for example if the lung is not able to fully re-expand. The study aims to look at whether it is possible to predict these problems before the procedure using ultrasound. If it is possible to find the answers to some of these questions it might be possible to prevent patients undergoing treatments which are not likely to benefit them. The study will use information already collected as part of clinical care, as well as questionnaires from patients receiving care at a variety of centres. The different features of these centres will also be considered in analysis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pleural Diseases

Currently open trials in the same condition.

NCT06790082 — The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma · Phase 2 · recruiting
NCT06964308 — Thoracoscopic Pleural Biopsy in Sohag University Hospital · NA · recruiting
NCT06180603 — Strategy for Prompt and Effective Thoracentesis in the Emergency Department · NA · recruiting
NCT06226909 — The Efficacy of Shear-wave Elastography-guided Biopsy for Diagnosis in Pleural Disease · NA · recruiting

Other University of Oxford trials

Trials by the same sponsor.

NCT05380388 — A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 ) · Phase 2 · not yet recruiting
NCT07470424 — A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults · Phase 1 · not yet recruiting
NCT07345910 — Environment, Pathogens, and Host Interactions in Melioidosis · not yet recruiting
NCT07434973 — Stratification and Treatment in Early Psychosis Study - PROMOTE · Phase 3 · not yet recruiting
NCT07460401 — 'Do Patient Characteristics Associate With Poor Outcome With Femoral Acetabular Impingement Syndrome (FAIS) Following Ph · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05910112 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oxford
Last refreshed: 18 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05910112.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing